Heterocyclic compounds

Details Heterocyclic compounds Heterocyclic compounds

2006-09-19

2006-09-19

Wilson, James D. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S266240

Reexamination Certificate

active

07109333

ABSTRACT:
A process for the preparation of a compound of formula (I)comprising the steps:(a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups,with a compound of formula (III)in-line-formulae description="In-line Formulae" end="lead"?UNH2  (III)in-line-formulae description="In-line Formulae" end="tail"?to prepare a compound of formula (IV)and subsequently (b) substituting the group R1by replacement of the leaving group L′.

REFERENCES:
patent: 4074057 (1978-02-01), Kawamatsu et al.
patent: 4166735 (1979-09-01), Pilgram et al.
patent: 5457105 (1995-10-01), Barker
patent: 5480883 (1996-01-01), Spada et al.
patent: 5616582 (1997-04-01), Barker
patent: 5646153 (1997-07-01), Spada et al.
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5773476 (1998-06-01), Chen et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 43 08 014 (1994-09-01), None
patent: 0 370 704 (1990-05-01), None
patent: 0 414 386 (1991-02-01), None
patent: 0 452 002 (1991-10-01), None
patent: 0534 341 (1993-03-01), None
patent: 0 566 226 (1993-10-01), None
patent: 86/06718 (1986-11-01), None
patent: 93/13097 (1993-06-01), None
patent: 93/17682 (1993-09-01), None
patent: 93/18035 (1993-09-01), None
patent: 94/04526 (1994-03-01), None
patent: 95/00511 (1995-01-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/19774 (1995-07-01), None
patent: 95/24190 (1995-09-01), None
patent: 96/09294 (1996-03-01), None
patent: 96/15118 (1996-05-01), None
patent: 96/16960 (1996-06-01), None
patent: 96/40142 (1996-12-01), None
patent: 97/03069 (1997-01-01), None
patent: 97/13771 (1997-04-01), None
patent: 97/18212 (1997-05-01), None
patent: 97/30034 (1997-08-01), None
patent: 98/02434 (1998-01-01), None
patent: 98/02437 (1998-01-01), None
patent: 98/02438 (1998-01-01), None
patent: 98/14451 (1998-04-01), None
Zydowsky et al., “Synthesis and In Vitro Evaluation of Fused Ring Heterocycle-Containing Angiotensin II Antagonists”, 1994, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 1, pp. 173-176.
Robba et al., “Thienopyrimidines—II Etude De La Thieno [3,2-d] Pyrimidine et de Quelques Derives”, 1971, Tetrahedron vol. 27, pp. 487-499.
Hunter, “A Thousand and One Protein Kinases”, Cell, vol. 50, pp. 823-829, 1987.
Modjtahedi et al., “EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN”, May 14, 1998, International Journal of Oncology, vol. 13, pp. 335-342.
Hung et al., “Basic Science of HER-2
eu: A Review”, Aug. 1999, Seminars in Oncology, vol. 26, No. 4, Suppl. 12, pp. 51-59.
J.R. Woodburn, “The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy”, 1999, Pharmacol Ther., vol. 82, Nos. 2-3, pp. 241-250.
Ullrich et al., “Signal Transduction by Receptors with Tyrosine Kinase Activity”, Apr. 20, 1990, Cell, vol. 61, pp. 203-212.
Bridges et al, “Tyrosine Kinase Inhibitors”, J Med. Chem., vol. 39, No. 1, Jan. 5, 1996, pp. 267-276.
Rewcastle et al., “Tyrosine Kinase Inhibitors”, J. Med. Chem., vol. 38, No. 18, 1995, pp. 3482-3487.
G.W. Rewcastle et al., “Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding sit inhibitors of the tyrosine kinase function of the epidermal growth factor receptor”, Journal of Medicinal Chemistry, 1996, vol. 39, No. 9, pp. 1823-1835.
Y. Katsura et al., “Studies on antiulcer drugs. V. Synthesis and antiulcer activity of aralkybenzozoles”, Chemical and Pharmaceutical Bulletin, 1992, vol. 40, No. 8, pp. 2062-2072.
T. Shoda et al., “Studies on antidiabetic agents. II. Synthesis of 5-[4-(methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its derivatives”, Chemical and Pharmaceutical Bulletin, 1982, vol. 30, pp. 3580-3600.
G.W. Rewcastle et al., “Synthesis of 6-substituted pyrido[3,d-d]pyrimidine-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives”, Journal of the Chemical Society, Perkins Transactions 1., 1996, pp. 2221-2226.
A.F. Wilks, Progress in Growth Factor Research, 1990, 2, pp. 97-111.
S.A. Courtneidge, Dev. Supp. I, 1993, pp. 57-64.
J.A. Cooper, Semin. Cell Biol., 1994, 5(6), pp. 377-387.
R.F. Paulson, Semin. Immunol., 1995, 7(4), pp. 267-277.
A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), pp. 394-401.
Dvir et al., J. Cell. Biol., 1991, 113, pp. 857-865.
Buchdunger et al., Proc. Natl. Acad. Sci. USA; 1991, 92, pp. 2558-2562.
Klausner and Samelson, Cell; 1991, 64, pp. 875-878.
Berkois, Blood; 1992, 79(9), pp. 2446-2454.
Salari et al., FEBS; 1990, 263(1), pp. 104-108.
Ohmichi et al., Biochemistry, 1992, 31, pp. 4034-4039.
L.K. Shawyer, DDT, 1997, 2(2), pp. 50-63.
Pharmaceutical Research, 1986, 3(6), p. 318.
C.E. Housecroft et al., Inorg. Chem., 1991, 30(1), pp. 125-130.
H. Sato et al., Bioorganic and Medicinal Chemistry Letters, 1995, 5(3), pp. 233-236.
J. Org. Chem., 1990, 55, pp. 1379-1390.
Helv. Chim. Acta., 1983, 66(4), p. 1046.
T.R. Kelly and F. Lang, Tetrahedron Lett., 36, 9293, 1995.
J. Chem. Soc., Chem. Commun., 1988, p. 560.
V.P. Semenov and A.N. Studenikov, “Synthesis of 7-iodo-4aminoquinoline derivatives”, Khim Geterotsikl. Soedin., 1980, Issue 7, pp. 972-975.
R. Dempsy and E. Skito, Biochemistry, 30, 1991, p. 8480.
J. Org. Chem., 1992, 57(11), pp. 3126-3131.
A. Lee and W-C Dai, Tetrahedron, 1997, 53(3), pp. 859-868.

Affiliated with

Also associated with

Rating

Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3606817